PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-100.00%
Negative revenue growth while TRVN stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
100.00%
Gross profit growth above 1.5x TRVN's 46.93%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
-2.59%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-2.59%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-10.34%
Negative net income growth while TRVN stands at 20.06%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-10.26%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-10.26%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.08%
Slight or no buybacks while TRVN is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.08%
Slight or no buyback while TRVN is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-93.84%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-94.42%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
81.91%
Positive long-term OCF/share growth while TRVN is negative. John Neff would see a structural advantage in sustained cash generation.
68.32%
Positive OCF/share growth while TRVN is negative. John Neff might see a comparative advantage in operational cash viability.
41.88%
Positive 3Y OCF/share CAGR while TRVN is negative. John Neff might see a big short-term edge in operational efficiency.
55.55%
Positive 10Y CAGR while TRVN is negative. John Neff might see a substantial advantage in bottom-line trajectory.
79.95%
Positive 5Y CAGR while TRVN is negative. John Neff might view this as a strong mid-term relative advantage.
56.07%
Positive short-term CAGR while TRVN is negative. John Neff would see a clear advantage in near-term profit trajectory.
188.20%
Below 50% of TRVN's 975.23%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
-69.82%
Negative 5Y equity/share growth while TRVN is at 88.15%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
327.49%
3Y equity/share CAGR 1.25-1.5x TRVN's 254.07%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.65%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-14.02%
We have a declining book value while TRVN shows 511.72%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-4.69%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
7.04%
R&D dropping or stable vs. TRVN's 15.11%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-5.63%
We cut SG&A while TRVN invests at 6.40%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.